000			01943 a2200565 4500
005			20250516083922.0
264		0	_c20121002
008			201210s 0 0 eng d
022			_a1462-0332
024	7		_a10.1093/rheumatology/kes038 _2doi
040			_aNLM _beng _cNLM
100	1		_aAnderson, Amy E
245	0	0	_aImmunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. _h[electronic resource]
260			_bRheumatology (Oxford, England) _cAug 2012
300			_a1397-406 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aArthritis, Rheumatoid _xcomplications
650	0	4	_aB-Lymphocytes _ximmunology
650	0	4	_aCD5 Antigens _ximmunology
650	0	4	_aCase-Control Studies
650	0	4	_aCohort Studies
650	0	4	_aFemale
650	0	4	_aFlow Cytometry
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aImmunity _xphysiology
650	0	4	_aImmunophenotyping
650	0	4	_aInfluenza Vaccines _xadministration & dosage
650	0	4	_aLymphocyte Count
650	0	4	_aLymphocyte Depletion
650	0	4	_aLymphopenia _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aT-Lymphocytes _ximmunology
650	0	4	_aThymus Gland _ximmunology
700	1		_aLorenzi, Alice R
700	1		_aPratt, Arthur
700	1		_aWooldridge, Tom
700	1		_aDiboll, Julie
700	1		_aHilkens, Catharien M U
700	1		_aIsaacs, John D
773	0		_tRheumatology (Oxford, England) _gvol. 51 _gno. 8 _gp. 1397-406
856	4	0	_uhttps://doi.org/10.1093/rheumatology/kes038 _zAvailable from publisher's website
999			_c21651406 _d21651406